Date: August 7-11, 2004
Location: Washingotn DC, USA
Symposium Web Page: www.headandneckcancer.org
Sponsors: The American Head and Neck Society
Who Should Attend: Recent Doctorates or mid career investigators (PhD, DrPH, MD, DNS, SCD or equivalent)
Objectives: Develop an understanding of current issues in the diagnosis in the, evaluation and treatment of head and neck neoplasms. Improve treatment strategies. Identify basic science advances in head and neck oncology research. Who should attend: head neck surgeons, otolaryngologists, plastic surgeons, oncologists, scientists, nurses, and other professionals interested in head and neck oncology.
Topics: The diagnosis, treatment, reconstruction, rehbilitation and basic sciences related to or involved with the head and neck surgery, and oncology.
Concepts in Meetings & Events
1805 Ardmore Blvd
Pittsburgh, PA 15221 USA
Continuing Education: Yes, credits TBD
Sep 19, 2014 - The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.
Sep 22, 2010